Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Medistem Industry/Academia Collaboration Leads to Nanotechnology Based "Cancer Vaccine": Peer-Reviewed Publication Demonstrates New Method of Treating Prostate Cancer Based on Nanoparticle-Loaded Dendritic Cells

Abstract:
Medistem Inc. (PINKSHEETS: MEDS) announced today it has co-authored a peer-reviewed publication disclosing a new approach to stimulating the immune system to kill tumor cells using a novel nanotechnology-based approach.

Medistem Industry/Academia Collaboration Leads to Nanotechnology Based "Cancer Vaccine": Peer-Reviewed Publication Demonstrates New Method of Treating Prostate Cancer Based on Nanoparticle-Loaded Dendritic Cells

San Diego, CA | Posted on April 14th, 2012

In the publication (PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses. International Journal of Nanomedicine, 7: 1475, 2012) Medistem and a team of collaborators demonstrated that nanoparticles could be used to deliver molecules found on tumors to specific cells of the immune system called "dendritic cells." These nanoparticle-loaded dendritic cells were then able to stimulate other cells of the immune system to directly kill tumors in the test tube and also in mice bearing prostate cancer.

"Cellular therapy is a clinical reality, for example, the company Dendreon developed the first therapeutic FDA-approved cancer vaccine Sipuleucel-T (Provenge) that is currently being used for treatment of patients with hormone-resistant prostate cancer. The data we published today provides ways of optimizing treatments such as Provenge," said Dr. Vladimir Bogin, President and Chairman of Medistem. "By using nanotechnology to specifically educate dendritic cells to activate the immune system in patients, it may be possible to develop more effective ways of treating cancer by leveraging the body's own resources."

The senior author of the publication, Dr. Boris Minev, is faculty at the Moores Cancer Center, and at the Division of Neurosurgery of the University of California, as well as Director of Immunotherapy and Translational Oncology at Genelux Corporation. Additional collaborators included the Laboratory of Biomaterials and Nanotechnology, University of California Riverside, the Division of Neurosurgery, of University of California Los Angeles, and the Chemistry Department at San Diego State University.

"For more than 4 years, I have thoroughly enjoyed collaborating with the Medistem Team, in areas including treatment of multiple sclerosis, cancer immunotherapy, rheumatoid arthritis, and now nanotechnology. The common theme of our collaboration is leveraging the body's own resources as a therapeutic," said Dr. Boris Minev. "In addition to the recently announced clinical trials for Medistem's Endometrial Regenerative Cell (ERC) universal donor stem cell, I am looking forward to clinical translation of other products of our collaboration."

To date Medistem and Dr. Minev have published 12 peer-reviewed papers together. Dr. Minev was co-author on Medistem's original paper describing human use of the ERC in patients with multiple sclerosis (click here for link www.translational-medicine.com/content/pdf/1479-5876-7-15.pdf), as well as several other basic research and clinical publication. Medistem has filed US provisional patent # 61/592,636 covering naturally-derived nanoparticles generated by ERC.

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

####

For more information, please click here

Contacts:
Lisa Brock
Director of Investor Relations

503.381.4618

Medistem Inc.
9255 Towne Centre Drive
Suite 450
San Diego, CA 92122
www.medisteminc.com
Twitter: @medistem

Copyright © Marketwire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Berkeley Lab Researchers Demonstrate First Size-based Chromatography Technique for the Study of Living Cells April 22nd, 2014

PETA science consortium to present hazard testing strategy at nanotoxicology meeting: High tech field ripe for use of sophisticated non-animal testing strategies April 22nd, 2014

Harris & Harris Group Notes the Receipt of Proceeds From the Sale of Molecular Imprints' Semiconductor Business to Canon April 22nd, 2014

National Space Society Congratulates SpaceX on the Success of CRS-3 and the First Flight of the Falcon 9R April 22nd, 2014

Nanomedicine

Cloaked DNA nanodevices survive pilot mission: Successful foray opens door to virus-like DNA nanodevices that could diagnose diseased tissues and manufacture drugs to treat them April 22nd, 2014

Berkeley Lab Researchers Demonstrate First Size-based Chromatography Technique for the Study of Living Cells April 22nd, 2014

Amino-functionalized carbon nanotubes act as a carrier for nerve growth factor April 21st, 2014

Newly-Produced Bone Cement Able to Carry Medicine April 21st, 2014

Announcements

Berkeley Lab Researchers Demonstrate First Size-based Chromatography Technique for the Study of Living Cells April 22nd, 2014

PETA science consortium to present hazard testing strategy at nanotoxicology meeting: High tech field ripe for use of sophisticated non-animal testing strategies April 22nd, 2014

Harris & Harris Group Notes the Receipt of Proceeds From the Sale of Molecular Imprints' Semiconductor Business to Canon April 22nd, 2014

National Space Society Congratulates SpaceX on the Success of CRS-3 and the First Flight of the Falcon 9R April 22nd, 2014

Interviews/Book Reviews/Essays/Reports/Podcasts/Journals

Nanomaterial Outsmarts Ions April 22nd, 2014

Vacuum Ultraviolet Lamp of the Future Created in Japan: First Solid-State Vacuum UV Phosphor, Described in APL-Materials, Promises Smaller, Safer, Longer Lasting, Low Power Lamps for Industrial Applications April 22nd, 2014

Berkeley Lab Researchers Demonstrate First Size-based Chromatography Technique for the Study of Living Cells April 22nd, 2014

Nanoreporters tell 'sour' oil from 'sweet': Rice University's hydrogen sulfide nanoreporters gather intel on oil before pumping April 22nd, 2014

Research partnerships

University of Waterloo Visits China to Strengthen Bonds With Research Partners April 21st, 2014

Novel stapled peptide nanoparticle combination prevents RSV infection, study finds April 17th, 2014

Scientists Capture Ultrafast Snapshots of Light-Driven Superconductivity: X-rays reveal how rapidly vanishing 'charge stripes' may be behind laser-induced high-temperature superconductivity April 16th, 2014

Scalable CVD process for making 2-D molybdenum diselenide: Rice, NTU scientists unveil CVD production for coveted 2-D semiconductor April 8th, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE